CPRX Share Price

Open 1.22 Change Price %
High 1.24 1 Day -0.02 -1.64
Low 1.16 1 Week -0.04 -3.23
Close 1.20 1 Month 0.07 6.19
Volume 322740 1 Year -0.98 -44.95
52 Week High 2.25
52 Week Low 0.51
CPRX Important Levels
Resistance 2 1.27
Resistance 1 1.24
Pivot 1.20
Support 1 1.16
Support 2 1.13
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DRYS 1.01 -36.48%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
MU 21.71 -2.73%
More..
NASDAQ USA Top Gainers Stocks
BGMD 0.07 133.33%
LOCM 0.09 50.00%
NFEC 1.28 40.66%
BASI 0.90 28.57%
URRE 2.68 27.62%
QKLS 0.14 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
GRVY 20.96 23.15%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX)

CPRX Technical Analysis 4
As on 19th Jan 2017 CPRX Share Price closed @ 1.20 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.99 & Strong Buy for SHORT-TERM with Stoploss of 1.12 we also expect STOCK to react on Following IMPORTANT LEVELS.
CPRX Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
CPRX Other Details
Segment EQ
Market Capital 44575204.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.catalystpharma.com
CPRX Address
CPRX
355 Alhambra Circle
Suite 1500
Coral Gables, FL 33134
United States
Phone: 305-529-2522
Interactive Technical Analysis Chart Catalyst Pharmaceutical Partners, Inc. ( CPRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Catalyst Pharmaceutical Partners, Inc.
CPRX Business Profile
Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. As of December 31, 2011, the Company had two drugs in development: CPP-109 and CPP-115. of December 31, 2011, it was evaluating its drug candidate, CPP-109 for the treatment of cocaine addiction. As of December 31, 2011, the Company was in the early stages of developing CPP-115, another GABA aminotransferase inhibitor. It has identified two market opportunities that can be exploited by pharmacotherapies that inhibit GABA-aminotransferase (GABA-AT): drug addiction and epilepsy.